First Manhattan
CLVS

First Manhattan’s Clovis Oncology, Inc. CLVS Stock Holding History

First Manhattan’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-101,100
Closed -$8.33M – 1542
2017
Q3 		$8.33M Sell
101,100
-700
-0.7% -$55.5K 0.05% 197
2017
Q2 		$9.53M Buy
+101,800
New +$6.23M 0.06% 182

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

First Manhattan's CLVS Position: Q4 2017 in Review

First Manhattan sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 101,100 shares — an estimated $8.33M sold.

First Manhattan first reported a position in CLVS in Q2 2017 and held it in 2 quarters. The position peaked at $9.53M in Q2 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • First Manhattan reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
  • First Manhattan sold 101,100 Clovis Oncology, Inc. shares in Q4 2017, an estimated $8.33M.
  • First Manhattan first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 2 quarters.
  • First Manhattan's Clovis Oncology, Inc. position peaked at $9.53M in Q2 2017.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on First Manhattan's 13F filing for Q4 2017, filed 22 Jan 2018.